HC Wainwright & Co. Reiterates Buy on SpyGlass Pharma, Maintains $37 Price Target
SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System
SpyGlass Pharma Announces Trial Results From Bimatoprost Drug Pad-IOL System In Participants With Mild-To-Moderate Open Angle Glaucoma Reduces Mean IOP By 37% Across All Three Dose Cohorts; 86% Participants Remained Off All Topical IOP-Lowering Drops
SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability
SpyGlass Pharma Acquires Advanced Vision Science For ~$13M In Cash
SpyGlass Pharma, Inc. (SGP) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
SpyGlass Pharma to Participate in Upcoming Investor Conferences
SpyGlass Pharma Celebrates Grand Opening of New Irvine Headquarters, Positioning Itself for First Product Launch and Custom R&D Space
Raymond James Initiates Coverage On SpyGlass Pharma with Outperform Rating, Announces Price Target of $39
SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
SpyGlass Pharma Appoints Shannon Treviño as General Counsel
SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing
SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System
SpyGlass Says AMA CPT Editorial Panel Approves New Add-On Category III CPT Code For Attachment, Insertion Of Intraocular Lens Prosthesis-Mounted Drug-Eluting Implant
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
SpyGlass Pharma Q1 EPS $(0.69) Misses $(0.42) Estimate
SpyGlass Pharma shares are trading lower after the company reported a year-over-year decrease in Q4 financial results.
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
